Eisai Wants Aurobindo's Generic Weight Loss Drug Blocked

Law360 (May 2, 2019, 5:28 PM EDT) -- Eisai Inc. has accused Aurobindo Pharma LTD in Delaware federal court of infringing six patents covering its weight loss drug Belviq.

Eisai, which licenses the patents, and Arena Pharmaceuticals Inc., which owns them, sued Wednesday after learning that Aurobindo had submitted an abbreviated new drug application to the U.S. Food and Drug Administration hoping to get its generic approved. The suing drugmakers want the generic version blocked until after the patents expire.

According to the FDA's Orange Book, five of the patents expire in 2023, and the other in 2031.

Aurobindo's ANDA had certified to the FDA that Arena's patents were...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!